Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)
Status:
Not yet recruiting
Trial end date:
2028-06-30
Target enrollment:
Participant gender:
Summary
Antenatal corticosteroids (ACS) reduce the risks of neonatal death and morbidities in preterm
infants, such as respiratory distress syndrome.
The standard of care for pregnant people at risk of preterm birth includes 2 doses of
Celestone (for a total of 24 mg in Canada, or 22.8 mg in Australia) to accelerate fetal lung
maturity.
The investigators plan to conduct a randomized controlled trial to determine whether half the
usual dose (12 mg in Canada, or 11.4 mg in Australia) of Celestone is non-inferior to the
standard double doses.
Phase:
Phase 4
Details
Lead Sponsor:
Hamilton Health Sciences Corporation
Collaborators:
Canadian Institutes of Health Research (CIHR) Population Health Research Institute